NEW YORK (GenomeWeb) – Cancer diagnostics company Empire Genomics announced today that it has received approval from New York State to offer molecular and cellular tumor marker testing through the state's Clinical Laboratory Evaluation Program (CLEP).

The company plans to offer genetic testing and molecular diagnostics to help physicians make treatment decisions for cancer patients. The CLEP program evaluates a clinical lab's ability to accurately and reliably deliver test results.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.